Table 4 Acute migraine prescription frequency on the G43* population, the list includes acute medication from both acute and prophylactic groups (N = 8244)
ATC | Medication | Group | N | Proportion of patients (%) |
|---|---|---|---|---|
N02CC01 | Sumatriptan | Selective serotonin (5HT1) agonists | 3962 | 48.06% |
M01AE02 | Naproxen | Antiinflammatory and antirheumatic products | 1698 | 20.60% |
N02CC07 | Frovatriptan | Selective serotonin (5HT1) agonists | 1227 | 14.88% |
N02CC04 | Ritsatriptan | Selective serotonin (5HT1) agonists | 989 | 12.00% |
M01AE01 | Ibuprofen | Antiinflammatory and antirheumatic products | 889 | 10.78% |
N02CC03 | Zolmitriptan | Selective serotonin (5HT1) agonists | 763 | 9.26% |
N02CC06 | Eletriptan | Selective serotonin (5HT1) agonists | 673 | 8.16% |
A03FA01 | Metoclopramide | Propulsives | 664 | 8.05% |
N02CC05 | Almotriptan | Selective serotonin (5HT1) agonists | 566 | 6.87% |
M01AG02 | Tolfenamic acid | Antiinflammatory and antirheumatic products | 530 | 6.43% |
N02BE01 | Paracetamol | Antiinflammatory and antirheumatic products | 391 | 4.74% |
M01AE03 | Ketoprofen | Antiinflammatory and antirheumatic products | 192 | 2.33% |
N02AA59 | Codein combnations | Opioids | 178 | 2.16% |
M01AB05 | Diclofenac | Antiinflammatory and antirheumatic products | 165 | 2.00% |
N02CC02 | Naratriptan | Antiinflammatory and antirheumatic products | 107 | 1.30% |
H02AB06 | Prednisolone | Corticosteroids for systemic use, plain | 95 | 1.15% |
M01AE17 | Dexketoprofen | Antiinflammatory and antirheumatic products | 70 | 0.85% |
N02AJ06 | Codeine and paracetamol | Opioids | 61 | 0.74% |
H02AB04 | Methylprednisolone | Corticosteroids for systemic use, plain | 48 | 0.58% |
N02BA01 | Acetylsalicylic acid | Other analgesics and antipyretics | 43 | 0.52% |
M01AB01 | Indometacin | Antiinflammatory and antirheumatic products | 38 | 0.46% |
M03 BC51 | Orfenadrine combinations | Muscle relaxants, centrally acting agents | 38 | 0.46% |
M01AH05 | Etoricoxib | Antiinflammatory and antirheumatic products | 26 | 0.32% |
M03BX02 | Tizanidine | Muscle relaxants, centrally acting agents | 24 | 0.29% |
M01AG01 | Mefenamic acid | Antiinflammatory and antirheumatic products | 21 | 0.25% |
A04AA01 | Ondansetron | Serotonin (5HT3) antagonists | 16 | 0.19% |
H02AB07 | Prednisone | Corticosteroids for systemic use, plain | 14 | 0.17% |
N02AX02 | Tramadol | Opioids | 14 | 0.17% |
H02AB02 | Dexametasone | Corticosteroids for systemic use, plain | 13 | 0.16% |
M01AE52 | Naproxen and Esomeprazole | Antiinflammatory and antirheumatic products | 12 | 0.15% |
A03DA02 | Pitofenone and Analgesics | Synthetic anticholinergic agents in combination with analgesics | 8 | 0.10% |
M01 AC06 | Meloksicam | Antiinflammatory and antirheumatic products | 5 | 0.06% |
M03 BC01 | Orfenadrine | Muscle relaxants, centrally acting agents | 5 | 0.06% |
N02AJ08 | Codein and ibuprofen | Opioids in combination with non-opioid analgesics | 4 | 0.05% |
M01AH01 | Celecoxib | Antiinflammatory and antirheumatic products | 3 | 0.04% |
N02BE51 | Paracetamol combinations | Antiinflammatory and antirheumatic products | 3 | 0.04% |
M01AB08 | Etodolac | Antiinflammatory and antirheumatic products | 1 | 0.01% |
M01AX01 | Nabumetone | Antiinflammatory and antirheumatic products | 1 | 0.01% |
M03BX01 | Baclofen | Muscle relaxants, centrally acting agents | 1 | 0.01% |
N02AX52 | Tramadol combinations | Opioids in combination | 1 | 0.01% |
N02BA51 | Acetylsalicylic acid, combinations | Other analgesics and antipyretics | 1 | 0.01% |